27 September, 2017
Moreover, Independent Port Consultants has 0.04% invested in Abbott Laboratories (NYSE:ABT) for 1,982 shares. Also, the company has received FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device recently. "Meanwhile, we await the closing of the Alere buyout, slated for the end of third quarter".
Several salient technical indicators of ABT are now starting to make their way into the trading conversation.
On July 21 Deutsche Bank maintained a company rating of "Buy" but raised the price target from $54.00 to $56.00.
In other Abbott Laboratories news, insider Jaime Contreras sold 52,700 shares of Abbott Laboratories stock in a transaction that occurred on Friday, September 22nd. RBC Capital Markets maintained the shares of ABT in report on Thursday, January 26 with "Outperform" rating. Finally, BidaskClub lowered shares of Abbott Laboratories from a buy rating to a hold rating in a research report on Sunday, August 6th.
Among 4 analysts covering Philippine Long Distance Telephone (NYSE:PHI), 3 have Buy rating, 1 Sell and 0 Hold.
Institutions own 73.41% of Abbott Laboratories (ABT)'s shares. California-based Bankshares Of Stockton has invested 0.31% in Abbott Laboratories (NYSE:ABT). The stock has a 50 day moving average price of $44.58 and a 200 day moving average price of $41.35. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued.
More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Seekingalpha.com which released: "Buy Abbott Laboratories - Cramer's Lightning Round (9/15/17)" on September 18, 2017, also Seekingalpha.com with their article: "Can Abbott Top Its All-Time High?" published on September 07, 2017, Thestreet.com published: "Alibaba, Qorvo, Abbott Laboratories, Square: "Mad Money" Lightning Round" on September 16, 2017. The healthcare product maker reported $0.62 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.60 by $0.02. Revenue during the quarter was $6.64 billion, representing 24% growth from $5.33 billion in year-ago quarter. During the same period in the previous year, the firm posted $0.55 EPS. Livingston Asset Management (Operating As Southport Cap Management) has invested 0.14% in Abbott Laboratories (NYSE:ABT). Indiana & Invest Management Com has invested 0.46% in Abbott Laboratories (NYSE:ABT). If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and global copyright & trademark law.
Additionally the company declared a dividend that will be paid on Wednesday the 15th of November 2017. Investors of record on Friday, April 14th will be paid a $0.265 dividend. The ex-dividend date is set for Wednesday the 12th of July 2017. The dividend will be $0.265 per share for the quarter or $1.06 on an annualized basis. Abbott Laboratories (NYSE:ABT) has risen 15.90% since September 27, 2016 and is uptrending. Burt Wealth Advsrs accumulated 3,181 shares or 0.11% of the stock. Overall, the share price is up 95.26% so far this year. A statistical measure of the dispersion of returns (volatility) for ABT producing salvation in Investors mouth, it has week volatility of 1.31% and for the month booked as 1.22%. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
In other Abbott Laboratories news, insider Brian J. Blaser sold 15,000 shares of Abbott Laboratories stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $750,000.00. Iberiabank owns 5,088 shares for 0.07% of their portfolio. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 270,850 shares of company stock worth $13,549,998. Corporate insiders own 0.76% of the company's stock.
Other analysts have also recently issued research reports about the company. Capital Research Global Investors grew its position in shares of Abbott Laboratories by 45.7% in the 2nd quarter. Abbott Laboratories accounts for 1.8% of Moody Lynn & Lieberson LLC's holdings, making the stock its 19th largest holding.
Analysts are speculating a 38.81% move, based on the high target price ($95) for the shares that is set to reach in the next 12 months. State Street Corp grew its position in shares of Abbott Laboratories by 18.9% in the 1st quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker's stock worth $264,000 after acquiring an additional 30 shares during the period.
Novare Capital Management Llc, which manages about $695.33M and $444.07M US Long portfolio, decreased its stake in Honeywell (NYSE:HON) by 2,680 shares to 67,414 shares, valued at $8.99M in 2017Q2, according to the filing.
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
